| Similar Articles |
|---|
 |
The Motley Fool
October 22, 2009
Robert Steyer |
Nibbles Here and There at Forest Labs Forest Laboratories banks on its usual strategy of licensing and collaboration to offset generic-drug threats.   |
The Motley Fool
October 6, 2008
Brian Orelli |
Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated. |
The Motley Fool
October 18, 2006
Brian Lawler |
Seeing the Forest Through the Trees Underappreciated Forest Labs continues its trend of strong growth. Trading at roughly 20 times its forward earnings guidance even with a much higher level of R&D spending, here is a company that investors shouldn't lose sight of amidst the rest of the trees. |
The Motley Fool
September 1, 2004
W.D. Crotty |
A Pall Falls Over Forest One of Forest Labs' Alzheimer's drugs fails in phase 3 trials. For investors willing to take the political risk, today's drug news has taken a battered stock, with a great balance sheet, to very reasonable price levels. |
The Motley Fool
January 18, 2012
Sean Williams |
This Company is Quickly Approaching the Patent Cliff Earnings exceed expectations at drug manufacturer Forest Laboratories, but worries about future sales mount. |
BusinessWeek
June 12, 2006
Gene G. Marcial |
New Growth At Forest? Forest Laboratories has been a drag among drugmakers. |
The Motley Fool
April 24, 2007
Ryan Fuhrmann |
Mixed Foliage at Forest Labs Here's what to look for as Forest Labs prepares for a big loss. Investors, take note. |
The Motley Fool
April 16, 2008
Brian Orelli |
Forest Labs' Race Against the Clock Investors don't seem to like Forest Labs' ambitious plans for research and development. |
The Motley Fool
January 16, 2008
Brian Orelli |
Forest Labs Not Down -- Yet Double-digit revenue growth is the highlight of a good quarter for Forest Labs, but the company will need a lot more than one solid quarter to get its stock growing again. |
The Motley Fool
October 5, 2004
W.D. Crotty |
Lots of Profits in This Forest Drug manufacturer Forest Laboratories, down sharply from its high, offers value and growth. |
